Tag Archives: Industry News

New CERES RANCHER device delivers smarter insights, stronger design, and improved efficiency for modern cattle producers across the U.S.

OVERLAND PARK, Kan. – April 28, 2025 – CERES TAG, the global leader in direct-to satellite animal tracking and livestock intelligence, has announced the launch of its newest product, the CERES RANCHER (TM). This advanced technology represents the latest advancement in a series of innovations designed to equip ranchers, producers, veterinarians, and researchers with powerful, real-time insights that strengthen cattle operations from pasture to plate.

Following strong growth in the U.S. market over the first half of 2025 and early success with key partnerships and distribution, CERES TAG has expanded its portfolio with a device that incorporates feedback from years of field use across global operations. The CERES RANCHER builds on the strengths of the original CERES RANCH device, delivering new functionality, durability, and simplicity to producers while maintaining the accuracy and reliability that has defined the company’s reputation.

“This is the next level of livestock intelligence to meet the future and current demands of ranching,” said David Smith, Co-Founder and CEO of CERES TAG. “We’ve listened to producers, researchers, and field experts around the world, and RANCHER is the result of this research. It delivers better analytical data, faster, and with greater ease of use.”

The CERES RANCHER includes improvements in battery performance and a stronger, more rugged housing. It features a simplified application process and a newly designed activation tool that improves alignment and reduces user error. Additionally, its updated algorithms now provide separately reported data for resting and ruminating behaviors, a critical development for producers and researchers seeking to better understand herd activity and efficiency.

As livestock operations across the U.S. face mounting pressure from reduced herd sizes and rising calf prices, tools like CERES RANCHER offer real advantages in herd management. With continuous insights into grazing, movement, health, and behavior, the device supports better decisions, streamlined labor, and increased profitability for producers of all sizes.

“Our platform is not just about location, it’s about insights that help producers be more productive and thrive in today’s competitive environment” Smith added. “We’re focused on improving productivity and profitability with every tag.”

CERES RANCHER will be available through approved distribution channels. The original CERES RANCH device will continue to be offered while supplies last, giving producers the flexibility to choose the product that best meets their operation’s needs.

CERES TAG continues to scale its presence across North America with the mission of redefining ranching through intelligence, not just tracking. With clients including Lykes Bros. Ranch in Florida and research collaborations with the University of Tennessee, the company is quickly establishing itself as an essential platform in modern livestock management.

CERES TAG is the world’s first direct-to-satellite animal health intelligence platform, delivering secure, real-time insights on cattle health, behavior, and location without the need for cellular networks or manual data collection. With operations across the U.S., Australia, and beyond, CERES TAG is reshaping how producers and researchers manage animal health, biosecurity, traceability, and profitability.

For more information about CERES TAG and its innovative solutions, visit www.cerestag.com.

---

About CERES TAG

CERES TAG is a pioneering Australian company specializing in direct-to-satellite animal monitoring technology. The company’s innovative solutions provide real-time tracking and data analytics for livestock and wildlife, enhancing productivity, profitability and sustainability in the agriculture and conservation sectors. | cerestag.com

Contact:
Cara Neill
cneill@jnaadv.com
913.327.0055

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-832-8175
Email: info@felixvet.com

Felixvet Launches Carprofen Soft Chewable Tablets  

Kansas City, Mo. — April 3, 2025 — As part of its commitment to enhance animal health, Felixvet has successfully launched Carprofen Soft Chewable Tablets, now available through animal health distributors. Felixvet, Inc., a generic companion animal pharmaceutical manufacturer based in Ireland, established its North American headquarters in Kansas City, Missouri, in 2023.

“We are excited to announce the launch of our fifth carprofen product offering in the U.S. market,” said Vince Palasota, President of North America at Felixvet. “This development marks a significant step forward in providing quality, affordable healthcare solutions for pets without sacrificing efficacy, safety or reliability.”

Felixvet is leading the animal health market by introducing Carprofen Soft Chewable Tablets to its portfolio of carprofen products. This addition offers veterinarians five different forms of carprofen, each specifically designed to meet the diverse needs of their customers.

“We are committed to introducing additional products that will help us become one of the leading companion animal generic drug companies globally,” states Palasota.

Carprofen Soft Chewable Tablets provide the same therapeutic benefits as other branded carprofen medications, but the new beef flavored Felixvet Soft Carprofen Chewable Tablets offer a state of the art, unique soft chewable tablet compared to the hard chewable tablet pioneer, RIMADYL®. They are easy to administer orally due to the palatable beef flavor. Felixvet’s Soft Chewable technology is based on traditional compression technology without the constraints imposed by current production processes such as extrusion or molding.

A nonsteroidal anti-inflammatory, Carprofen Soft Chewable Tablets relieve pain and inflammation associated with osteoarthritis. The tablets are therapeutically equivalent to the pioneer drug, RIMADYL®, with the same safety and efficacy. Available in three strengths, 25, 75 and 100 mg, each tablet is scored for easy and accurate dosing.

For more information, visit Felixvet.com or info@felixvet.com.

---

About Felixvet: 

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-832-8175
Email:info@felixvet.com

Felixvet Announces New Hires to Lead Sales

Kansas City, Mo. — March 18, 2025 — Felixvet, Inc., an Ireland-based generic companion animal pharmaceutical manufacturer, established its North American headquarters in Kansas City, Mo., in 2023, is pleased to announce the addition of Matthew Maggio and Michael Morelli as Directors of Corporate Accounts for North America. In their new roles, Maggio and Morelli will execute strategic sales plans, foster long-term partnerships, collaborate with distributor partners and drive business growth through creative marketing solutions.

Matthew Maggio has nearly two decades of experience leading high-performing teams in the pharmaceutical industry, including MWI Animal Health, Elanco and Boehringer Ingelheim Vetmedica, Inc.

Before joining Felixvet, Maggio launched his career in sales and quickly rose through the ranks to become a top-producing salesperson and account manager. Throughout his career, he has consistently excelled in competitive markets, leveraging his extensive technical knowledge in animal immunology, pharmaceuticals and product marketing to drive success.

Michael Morelli brings a wealth of experience, having previously served as a National Account Manager and Sales Director, where he successfully drove large-scale account growth and managed high-performing teams. Morelli has honed his leadership and strategic sales skills, overseen regional operations and cultivating strong customer relationships.

Before joining Felixvet, Morelli held leadership roles at Terumo Medical Corporation, IQVIA and Takeda Pharmaceuticals North America, where he successfully developed and motivated high-performing teams. Throughout his career, he has worked closely with animal health distributors and veterinarians, forging strategic partnerships to drive business growth and innovation.

“We are very pleased to have both Matthew Maggio and Michael Morelli join the team at Felixvet. Together, they bring over 40 years of experience in pharmaceutical industry sales and have a proven track record of success,” said Vince Palasota, President of Felixvet North America. “Their expertise will be instrumental in helping us achieve our growth objectives. With a wealth of experience in sales management and team leadership, they will help us on our mission to advance veterinary care by offering straight generics, value-added products, and novel solutions.”

For more information, visit Felixvet.com or info@felixvet.com.

---

About Felixvet: 

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bio-equivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in the North American markets, upon approval by the Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

The complexity of OA can make it hard to diagnose and treat, but a new resource that promotes pet owner involvement in joint disease detection can help streamline the process.

SHIRLEY, N.Y., Feb. 13, 2025 — American Regent, maker of Adequan® Canine (polysulfated glycosaminoglycan), is proud to announce the launch of a new canine osteoarthritis (OA) treatment protocol guide for veterinary practices. The guide provides veterinarians with a framework for creating a standardized approach to diagnosing and treating canine joint disease. The protocol guide was developed in collaboration with Denis Marcellin-Little, DEDV, DACVS, DACVSMR, DECVS.

“Structure and consistency are very important,” says Dr. Marcellin-Little, professor of orthopedics at University of California, Davis. “By emphasizing a practical, step-by-step framework, we’re moving beyond philosophical guidelines to something that truly helps practitioners and pet owners manage OA over the long term.”

The complexity of OA, combined with the time constraints veterinary practices face, makes having a comprehensive solution for arthritis paramount—an approach many veterinarians support. In fact, 95% of 327 veterinarians who participated in an American Animal Hospital Association survey said implementing a canine OA protocol would be helpful or is important/necessary.

American Regent Animal Health developed this framework for canine OA management with all veterinary practices in mind. The introductory guide showcases a three-step plan to help develop and implement an OA treatment protocol in almost any clinic. This plan includes:

– How to take a proactive approach to OA diagnosis
– Insights on how to establish a standardized OA treatment plan approach
– Tips for implementing an OA protocol into clinic operations

The protocol guide also offers potential examples of multimodal treatment plans for the different stages of OA, organized around three categories: 1) treating the disease with FDA-approved Adequan® Canine, 2) managing associated pain and inflammation with products that may include anti-NGF monoclonal antibodies and/or NSAIDs, and 3) recommendations for lifestyle modifications and adjunct therapies.

There’s more than just pain management for treating OA

Often by the time joint disease is diagnosed, dogs are already showing significant signs of pain, and by then the damage can be detrimental to mobility. That’s why this protocol guide highlights a proactive approach to help detect the disease early. It recommends making dog owners a central part of the OA detection team and provides resources to help veterinarians educate their clients about the signs of OA.

“By engaging pet owners in the process, they can work together with their veterinarian to spot the subtle signs sooner and take steps that will make a real difference in the well-being of their dog with OA,” says Paris Revoir, DVM, Professional Service Veterinarian at American Regent Animal Health.

The OA Protocol Pack includes:
– A Canine Osteoarthritis Treatment Protocol Guide for Veterinary Practices
– A “Symptoms and Stages of OA” poster
– “Take the OA Quiz” window clings
– A personalized treatment tear pad

While canine arthritis presents differently in each case, the one thing that stays consistent is its potential to advance to debilitation and mobility loss if left untreated. These new OA protocol assets can help equip veterinarians and pet owners with the knowledge needed to detect the disease early—which can make all the difference. To order the Protocol Pack, visit oaprotocolpack.com. To learn more about Adequan® Canine, visit adequancanine.com.

Adequan® Canine polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL

Indications and Usage Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information.

---

About American Regent Animal Health

American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group
Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio.

For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 1-800-458-0163.

---

Reference
1AAHA Canine Osteoarthritis Survey Summary of Findings. October 2023. Survey done in
partnership with American Regent Animal Health. Data on file.